Methotrexate diethyl ester-loaded lipid-core nanocapsules in aqueous solution increased antineoplastic effects in resistant breast cancer cell line

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 1583-1591

  Yurgel, Virginia C ^a   Oliveira, Catiuscia P ^b   Begnini, Karine R ^a   Schultze, Eduarda ^a   Thurow, Helena S ^a   Leon, Priscila M M ^a   Dellagostin, Odir A ^a   Campos, Vinicius F ^a   Beck, Ruy C R ^b   Guterres, Silvia S ^b   Collares, Tiago ^a   Pohlmann, Adriana R ^b   Seixas, Fabiana K ^a  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Apoptotic cell death; Cell cycle arrest; Drug delivery; Drug targeting; MTX derivative; Nanocarriers; Resistance

Indexed keywords

LIPID; LIPID CORE NANOCAPSULE; METHOTREXATE DERIVATIVE; METHOTREXATE DIETHYL ESTER; NANOCAPSULE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL STRAIN MCF 7; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOENCAPSULATION; S PHASE CELL CYCLE CHECKPOINT; TREATMENT RESPONSE;

APOPTOTIC CELL DEATH; CELL CYCLE ARREST; DRUG DELIVERY; DRUG TARGETING; MTX DERIVATIVE; NANOCARRIERS; RESISTANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTERIFICATION; HUMANS; LIPIDS; METHOTREXATE; NANOCAPSULES; SOLUTIONS; TREATMENT OUTCOME; WATER;

EID: 84897052301     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S56506     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012;15(4):183-210.
3. Visentin M, Zhao R, Goldman ID. The antifolates. Hematol Oncol Clin North Am. 2012;26(3):629-648, ix.
4. Zhao R, Goldman ID. Resistance to antifolates. Oncogene. 2003;22(47): 7431-7457.
5. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta. 2002;1587(2-3):164-173.
6. Yoon SA, Choi JR, Kim JO, Shin JY, Zhang X, Kang JH. Influence of reduced folate carrier and dihydrofolate reductase genes on methotrexate-induced cytotoxicity. Cancer Res Treat. 2010;42(3):163-171.
7. Selga E, Oleaga C, Ramirez S, de Almagro MC, Noe V, Ciudad CJ. Networking of differentially expressed genes in human cancer cells resistant to methotrexate. Genome Med. 2009;1(9):83.
8. Moscow JA, Connolly T, Myers TG, Cheng CC, Paull K, Cowan KH. Reduced folate carrier gene (RFC1) expression and anti-folate resistance in transfected and non-selected cell lines. Int J Cancer. 1997;72(1): 184-190.
9. Yang R, Li WW, Hoang BH, et al. Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier. BMC Cancer. 2008;8:124.
10. Santos MA, Enyedy EA, Nuti E, Rossello A, Krupenko NI, Krupenko SA. Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007;15(3):1266-1274.
11. Moura JA, Valduga CJ, Tavares ER, Kretzer IF, Maria DA, Maranhao RC. Novel formulation of a methotrexate derivative with a lipid nanoemulsion. Int J Nanomedicine. 2011;6:2285-2295.
12. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-760.
13. Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11 Suppl 2: S81-S91.
14. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26(5):1025-1058.
15. Mora-Huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385(1-2):113-142.
16. Jager E, Venturini CG, Poletto FS, et al. Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J Biomed Nanotechnol. 2009;5(1):130-140.
17. Muller CR, Schaffazick SR, Pohlmann AR, et al. Spray-dried diclofenac-loaded poly(epsilon-caprolactone) nanocapsules and nanospheres. Preparation and physicochemical characterization. Pharmazie. 2001;56(11):864-867.
18. Cruz L, Schaffazick SR, Dalla CT, et al. Physico-chemical characterization and in vivo evaluation of indomethacin ethyl ester-loaded nanocapsules by PCS, TEM, SAXS, interfacial alkaline hydrolysis and antiedematogenic activity. J Nanosci Nanotechnol. 2006;6(9-10): 3154-3162.
19. Fiel L, Rebelo L, Santiago T, et al. Diverse deformation properties of polymeric nanocapsules and lipid-core nanocapsules. Soft Matter. 2011;7:7240-7247.
20. Venturini C, Jäger E, Oliveira C, et al. Formulation of lipid core nanocapsules. Colloids Surf A Physicochem Eng Asp. 2011;375: 200-208.
21. Jornada DS, Fiel L, Bueno K, et al. Lipid-core nanocapsules: mechanism of self-assembly, control of size and loading capacity. Soft Matter. 2012;8:6646-6655.
22. Figueiro F, Bernardi A, Frozza RL, et al. Resveratrol-loaded lipid-core nanocapsules treatment reduces in vitro and in vivo glioma growth. J Biomed Nanotechnol. 2013;9(3):516-526.
23. Bernardi A, Frozza RL, Horn AP, et al. Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation. Neurochem Int. 2010;57(6):629-636.
24. Bernardi A, Zilberstein AC, Jager E, et al. Effects of indomethacin-loaded nanocapsules in experimental models of inflammation in rats. Br J Pharmacol. 2009;158(4):1104-1111.
25. Bernardi A, Braganhol E, Jager E, et al. Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 2009;281(1):53-63.
26. Pohlmann AR, Fonseca FN, Paese K, et al. Poly(-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin Drug Deliv. 2013;10(5):623-638.
27. Bulcao RP, Freitas FA, Venturini CG, et al. Acute and subchronic toxicity evaluation of poly(epsilon-caprolactone) lipid-core nanocapsules in rats. Toxicol Sci. 2013;132(1):162-176.
28. Oliveira C, Venturini C, Donida B, Poletto F, Guterres SS, Pohlmann AR. An algorithm to determine the mechanism of drug distribution in lipid-core nanocapsule formulations. Soft Matter. 2013;9:1141-1150.
29. Allen RT, Hunter WJ III, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods. 1997;37(4):215-228.
30. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine. 2008;4(4):273-282.
31. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug Discov Today. 2010;15(19-20):842-850.
32. Mei L, Zhang Y, Zheng Y, et al. A novel docetaxel-loaded poly (epsilon-caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett. 2009;4(12): 1530-1539.
33. Stojanović Z, Marković S, Uskoković D. Determination of particle size distributions by laser diffraction. Technics New Mater. 2012;21: 11-20.
34. Berne BJ, Pecora R. Dynamic light scattering: with applications to chemistry, biology and physics. New York: Wiley, c 1976.
35. Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res. 2010;27(5):796-810.
36. Zanotto-Filho A, Coradini K, Braganhol E, et al. Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur J Pharm Biopharm. 2013;83:156-167.
37. Nogueira DR, Tavano L, Mitjans M, Perez L, Infante MR, Vinardell MP. In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles. Biomaterials. 2013;34(11):2758-2772.
38. Bernardi A, Frozza RL, Hoppe JB, et al. The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathways. Int J Nanomedicine. 2013;8:711-728.
39. Rastogi N, Mishra DP. Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div. 2012;7(1):26.